share_log

22nd Century Raises $1.68 Million in Regulation A Offering, Amends Senior Secured Credit Facility

22nd Century Raises $1.68 Million in Regulation A Offering, Amends Senior Secured Credit Facility

22世紀在《A類規定》發行中籌集了168萬美元,修改了高級擔保信貸安排
newsfile ·  08/28 21:10

Mocksville, North Carolina--(Newsfile Corp. - August 28, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced that it has secured an additional $1.68 million in gross proceeds from institutional investors through its Regulation A offering priced at $0.57 and from a separate private placement of common warrants. The Company also entered into an amendment to its existing debentures held by JGB Partners and related entities ("JGB").

北卡羅來納州莫克斯維爾-(新聞稿 - 2024年8月28日)- 22nd Century Group, Inc. (納斯達克: XXII) ,一家專注於尼古丁傷害減少和合同製造的菸草產品公司,今天宣佈成功完成了另有168萬美元的投資,來自機構投資者們通過其定向增發(Regulation A offering)以0.57美元的價格,並通過獨立的定向增發來實現。該公司還與JGb Partners和相關實體("JGB")達成了對現有債券的修訂。

Under the terms of the amended debenture agreements, JGB suspended provisions of the Debentures requiring 20% of any equity issuances to be paid to the Holders through December 31, 2024. Additionally, JGB will limit its monthly redemption right to not more than 50% of the amounts allowed beginning in August 2024 and through July 2025.

根據修訂債券協議的條款,JGb暫停了到2024年12月31日之前支付20%權益發行份額給持有人的規定。此外,JGb將在2024年8月及2025年7月前限制其每月贖回權不超過允許金額的50%。

"Accessing additional capital and amending the repayment terms of our Senior Secured Credit Facility enables 22nd Century Group to remain focused on the continued scaling of our contract manufacturing business, while at the same time reactivating and expanding our FDA authorized VLN reduced nicotine content product line in the markets," said Larry Firestone, Chairman and CEO.

"獲取額外資金並修改我們的優先有擔保信貸設施的還款條款,使22nd Century Group能夠繼續專注於擴大我們的合同製造業務,同時激活和擴展我們在市場上的FDA授權的低尼古丁含量產品系列," Larry Firestone,董事長兼首席執行官說道。

About 22nd Century Group, Inc.

關於22世紀集團公司

22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction by offering tobacco products with 95% less nicotine, designed to improve health and wellness by helping smokers smoke less. Backed by comprehensive and extensively patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, the Company has pioneered the development of high-yield, proprietary reduced nicotine content (RNC) tobacco plants and clinically validated RNC cigarette products. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of both its own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.

22世紀集團股份有限公司 (NASDAQ: XXII) 是一家農業生物科技公司,專注於通過提供含有95%較少尼古丁的菸草產品以減少菸草危害,並旨在通過幫助吸菸者減少吸菸來改善健康和健康狀況。該公司通過對菸草植物中尼古丁生物合成活動進行全面和廣泛的專利技術調控,開創了高產量的專有減少尼古丁含量 (RNC) 菸草植物和經過臨床驗證的 RNC 菸捲產品的研發先河。該公司於2021年12月獲得了第一個和唯一授予可燃菸捲的 FDA 修改危險菸草產品 (MRTP) 許可。該公司是大衆和康卡斯特訴訟達成的大衆和康卡斯特協議的後續參與制造商,與自己的產品和合同製造業務 ("CMO") 垂直整合,其主要由品牌過濾雪茄和傳統香菸組成。

Learn more at xxiicentury.com, on X, on LinkedIn, and on YouTube.
Learn more about VLN at tryvln.com.

請訪問 xxiicentury.com、X、LinkedIn 和 YouTube 了解更多信息。
了解有關VLN的更多信息,請訪問 tryvln.com。

Cautionary Note Regarding Forward-Looking Statements

關於前瞻性聲明的謹慎說明

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024, and in the Company's Quarterly Reports filed on May 15, 2024 and August 13, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

除了歷史信息,此新聞稿中包含的所有陳述、預期和假設均爲前瞻性陳述,包括但不限於我們全年業務展望。前瞻性陳述通常包含諸如"預計"、"相信"、"考慮"、"繼續"、"可能"、"估計"、"期待"、"探索"、"預見"、"目標"、"指導"、"打算"、"可能"、"計劃"、"潛在"、"預測"、"初步"、"有可能"、"項目"、"有希望"、"尋求"、"應當"、"將會"、"將要"等表達。前瞻性陳述包括但不限於,關於我們的成本降低措施、關於監管執行的預期(包括我們能否獲得新規定的豁免)、關於我們的財務和運營業績以及關於我們的業務中斷保險索賠的預期的陳述。實際結果可能與前瞻性陳述中明確或暗示的結果有實質性差異。可能導致實際結果與前瞻性陳述有實質性差異的重要因素已在公司於 2024 年 3 月 28 日提交的年度報告第 10-k 表中的"風險因素"中闡明,並在公司於 2024 年 5 月 15 日和 2024 年 8 月 13 日提交的季度報告中闡明。本發佈中提供的所有信息都是截至本文日期的,並且公司不承擔任何義務並且無意更新這些前瞻性陳述,除非法律另有要求。

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

投資者關係與媒體聯繫
Matt Kreps
投資者關係
22世紀集團
mkreps@xxiicentury.com
214-597-8200

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論